Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002193 · ClinicalTrials.gov registry record · Phase 3
Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors
A Phase 3 study of HIV Infections, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 3
- Development phase
- 210
- Enrollment target
- 2
- Study locations
NCT00002193 is a Phase 3 study of HIV Infections that has completed, run by Glaxo Wellcome. The registered enrollment target is 210 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (53% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00002193, a Phase 3 study of HIV Infections, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 210 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to see if it is safe and effective to add a new protease inhibitor (PI), 141W94, to an anti-HIV regimen that includes 2 nucleoside reverse transcriptase inhibitors (NRTIs).
Conditions Studied
Interventions
- DRUG Amprenavir
Study Locations (2)
Florida
- Children's Diagnostic Treatment Ctr - Fort Lauderdale
Tennessee
- Saint Jude Children's Hosp / Dept of Infect Diseases - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002193
The ClinicalTrials.gov registry entry for NCT00002193 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (53% lower). The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Amprenavir is the first listed.
NCT00002193 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00002193 about?
NCT00002193 is a clinical study titled "Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors". The purpose of this study is to see if it is safe and effective to add a new protease inhibitor (PI), 141W94, to an anti-HIV regimen that includes 2 nucleoside reverse transcriptase inhibitors (NRTIs).
What is the current status of trial NCT00002193?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 210 participants.
What conditions does trial NCT00002193 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002193?
The interventions under investigation include: Amprenavir (DRUG).
Who is sponsoring clinical trial NCT00002193?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002193 being conducted?
This trial has 2 study locations across Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.